Publication | Closed Access

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase

Chronic PhaseHematological MalignancyOncologyPhase Ii TrialOral Cytarabine OcfosfateHematologyPharmacologyClinical TrialsMyeloid NeoplasiaPharmacotherapyMedicineCancer ResearchHealth Sciences